Exploring Predictive Biomarkers for ADC Drug-Induced Pulmonary Toxicities: The Enhertu Experience
- Overviewing biomarkers for ADC drug induced pulmonary toxicities
- Bridging non-clinical toxicology findings and clinical translational safety research
- Case study: Assessing ILD concerns in HER2-targeted ADCs to explore how biomarkers in blood helping refine prediction and how can we monitor and treat ADC toxicities